Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromorphone ER vs Oxycodone ER Adherence in Moderate to Severe Cancer Pain
ChiCTR2600126198Phase 4Not yet recruiting
- Sponsor
- Quanzhou First Hospital
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of hydromorphone in cancer pain (2 arms), sponsored by Quanzhou First Hospital. Primary endpoints: Morisky 8-item Medication Adherence Scale (MMAS-8) at week 12 and Proportion of Days Covered at week 12. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
hydromorphone
03
Conditions
cancer pain
Beyond the preview
Go deeper on ChiCTR2600126198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126198.